Download PDF
Am J Perinatol 2018; 35(14): 1366-1375
DOI: 10.1055/s-0038-1660462
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Practical Challenges of Diagnosis and Treatment Options in Persistent Pulmonary Hypertension of the Newborn: A Developing Country's Perspective

Narongsak Nakwan
1   Department of Pediatrics, Hat Yai Medical Education Center, Hat Yai Hospital, Hat Yai, Songkhla, Thailand
› Author Affiliations Funding None.
Further Information

Publication History

02 February 2018

02 May 2018

Publication Date:
19 June 2018 (online)

    Permissions and Reprints

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is a complication of several respiratory diseases characterized by an elevation in pulmonary vascular resistance with resultant right-to-left shunting of blood and severe hypoxemia in the neonatal period. PPHN carries a high rate of morbidity and mortality, particularly in limited-resource settings (low-income and/or developing country). Echocardiography remains the gold standard for diagnosis of PPHN. Modern therapies such as inhaled nitric oxide, high-frequency oscillatory ventilation, extracorporeal membrane oxygenation, and/or other pulmonary vasodilators agents can reduce the mortality rate of PPHN. Unfortunately, echocardiography and the use of these modern therapies are often difficult for a medical institution to provide for patients in developing countries, even when a timely diagnosis of PPHN has been made. In this review, the practical challenges of timely diagnosis of PPHN and efficient use of available treatment options faced by pediatricians or neonatologists in limited-resource settings are discussed.

Keywords

persistent pulmonary hypertension of the newborn - developing country - diagnosis - management - newborn
 

  • References

  • 1 Khorana M, Yookaseam T, Layangool T, Kanjanapattanakul W, Paradeevisut H. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at Queen Sirikit National Institute of Child Health. J Med Assoc Thai 2011; 94 (Suppl. 03) S64-S73
    PubMedGoogle Scholar
  • 2 Nakwan N, Pithaklimnuwong S. Acute kidney injury and pneumothorax are risk factors for mortality in persistent pulmonary hypertension of the newborn in Thai neonates. J Matern Fetal Neonatal Med 2016; 29 (11) 1741-1746
    CrossrefPubMedGoogle Scholar
  • 3 Walsh-Sukys MC, Tyson JE, Wright LL. , et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105 (1 Pt 1): 14-20
    CrossrefPubMedGoogle Scholar
  • 4 Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, Partridge JC, Rogers EE, Keller RL. Persistent pulmonary hypertension of the newborn in late preterm and term infants in California. Pediatrics 2017; 139 (01) e20161165
    CrossrefPubMedGoogle Scholar
  • 5 Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2017; 1: CD000399
    PubMedGoogle Scholar
  • 6 Sadiq HF, Mantych G, Benawra RS, Devaskar UP, Hocker JR. Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. J Perinatol 2003; 23 (02) 98-103
    CrossrefPubMedGoogle Scholar
  • 7 Schaible T, Hermle D, Loersch F, Demirakca S, Reinshagen K, Varnholt V. A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center. Intensive Care Med 2010; 36 (07) 1229-1234
    CrossrefPubMedGoogle Scholar
  • 8 Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2017; 8: CD005494
    Google Scholar
  • 9 Maneenil G, Thatrimontrichai A, Janjindamai W, Dissaneevate S. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn. Pediatr Neonatol 2018; 59 (01) 58-64
    CrossrefPubMedGoogle Scholar
  • 10 Nakwan N, Choksuchat D, Saksawad R, Thammachote P, Nakwan N. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr 2009; 98 (10) 1683-1685
    CrossrefPubMedGoogle Scholar
  • 11 Boo NY, Rohana J, Yong SC, Bilkis AZ, Yong-Junina F. Inhaled nitric oxide and intravenous magnesium sulphate for the treatment of persistent pulmonary hypertension of the newborn. Singapore Med J 2010; 51 (02) 144-150
    PubMedGoogle Scholar
  • 12 McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 2006; 21 (02) 217-222
    CrossrefPubMedGoogle Scholar
  • 13 Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol 2014; 38 (02) 78-91
    CrossrefPubMedGoogle Scholar
  • 14 Simonneau G, Gatzoulis MA, Adatia I. , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D34-D41
    CrossrefPubMedGoogle Scholar
  • 15 Bearer C, Emerson RK, O'Riordan MA, Roitman E, Shackleton C. Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ Health Perspect 1997; 105 (02) 202-206
    CrossrefPubMedGoogle Scholar
  • 16 Alano MA, Ngougmna E, Ostrea Jr EM, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001; 107 (03) 519-523
    CrossrefPubMedGoogle Scholar
  • 17 Grigoriadis S, Vonderporten EH, Mamisashvili L. , et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014; 348: f6932
    CrossrefPubMedGoogle Scholar
  • 18 Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120 (02) e272-e282
    CrossrefPubMedGoogle Scholar
  • 19 Lakshminrusimha S, Konduri GG, Steinhorn RH. Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates. J Perinatol 2016; 36 (Suppl. 02) S12-S19
    PubMedGoogle Scholar
  • 20 Bendapudi P, Rao GG, Greenough A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr Respir Rev 2015; 16 (03) 157-161
    PubMedGoogle Scholar
  • 21 Fraisse A, Geva T, Gaudart J, Wessel DL. Doppler echocardiographic predictors of outcome in newborns with persistent pulmonary hypertension. Cardiol Young 2004; 14 (03) 277-283
    CrossrefPubMedGoogle Scholar
  • 22 Puthiyachirakkal M, Mhanna MJ. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review. Front Pediatr 2013; 1: 23
    PubMedGoogle Scholar
  • 23 Narang A, Bhakoo ON, Nair PM, Bhandari V. Persistent pulmonary arterial hypertension of the newborn. Indian J Pediatr 1992; 59 (06) 735-739
    CrossrefPubMedGoogle Scholar
  • 24 Farrow KN, Groh BS, Schumacker PT. , et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008; 102 (02) 226-233
    CrossrefPubMedGoogle Scholar
  • 25 Farrow KN, Lakshminrusimha S, Reda WJ. , et al. Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295 (06) L979-L987
    CrossrefPubMedGoogle Scholar
  • 26 Lakshminrusimha S, Swartz DD, Gugino SF. , et al. Oxygen concentration and pulmonary hemodynamics in newborn lambs with pulmonary hypertension. Pediatr Res 2009; 66 (05) 539-544
    CrossrefPubMedGoogle Scholar
  • 27 Nagaya N, Nishikimi T, Okano Y. , et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31 (01) 202-208
    CrossrefPubMedGoogle Scholar
  • 28 Shah N, Natarajan G, Aggarwal S. B-type natriuretic peptide: biomarker of persistent pulmonary hypertension of the newborn?. Am J Perinatol 2015; 32 (11) 1045-1049
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clin Perinatol 1999; 26 (03) 601-619
    CrossrefPubMedGoogle Scholar
  • 30 Morin III FC, Egan EA, Ferguson W, Lundgren CE. Development of pulmonary vascular response to oxygen. Am J Physiol 1988; 254 (3 Pt 2): H542-H546
    PubMedGoogle Scholar
  • 31 Nakwan N, Chaiwiriyawong P. An international survey on persistent pulmonary hypertension of the newborn: a need for an evidence-based management. J Neonatal Perinatal Med 2016; 9 (03) 243-250
    PubMedGoogle Scholar
  • 32 Kinsella JP, Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995; 126 (06) 853-864
    CrossrefPubMedGoogle Scholar
  • 33 Oca MJ, Nelson M, Donn SM. Randomized trial of normal saline versus 5% albumin for the treatment of neonatal hypotension. J Perinatol 2003; 23 (06) 473-476
    CrossrefPubMedGoogle Scholar
  • 34 Lynch SK, Mullett MD, Graeber JE, Polak MJ. A comparison of albumin-bolus therapy versus normal saline-bolus therapy for hypotension in neonates. J Perinatol 2008; 28 (01) 29-33
    CrossrefPubMedGoogle Scholar
  • 35 Jaillard S, Houfflin-Debarge V, Riou Y. , et al. Effects of catecholamines on the pulmonary circulation in the ovine fetus. Am J Physiol Regul Integr Comp Physiol 2001; 281 (02) R607-R614
    CrossrefPubMedGoogle Scholar
  • 36 Liet JM, Boscher C, Gras-Leguen C, Gournay V, Debillon T, Rozé JC. Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus. J Pediatr 2002; 140 (03) 373-375
    CrossrefPubMedGoogle Scholar
  • 37 Rozé JC, Tohier C, Maingueneau C, Lefèvre M, Mouzard A. Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child 1993; 69 (1 Spec No): 59-63
    CrossrefPubMedGoogle Scholar
  • 38 Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database Syst Rev 2003; 3 (03) CD001242
    PubMedGoogle Scholar
  • 39 Magnenant E, Jaillard S, Deruelle P. , et al. Role of the alpha2-adrenoceptors on the pulmonary circulation in the ovine fetus. Pediatr Res 2003; 54 (01) 44-51
    CrossrefPubMedGoogle Scholar
  • 40 Tulloh RM, Dyamenahalli U, Stuart-Smith K, Haworth SG. Adrenoceptor-stimulated endothelium-dependent relaxation in porcine intrapulmonary arteries. Pulm Pharmacol 1994; 7 (05) 299-303
    CrossrefPubMedGoogle Scholar
  • 41 Wilson LE, Levy M, Stuart-Smith K, Haworth SG. Postnatal adrenoreceptor maturation in porcine intrapulmonary arteries. Pediatr Res 1993; 34 (05) 591-595
    CrossrefPubMedGoogle Scholar
  • 42 Tourneux P, Rakza T, Bouissou A, Krim G, Storme L. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. J Pediatr 2008; 153 (03) 345-349
    CrossrefPubMedGoogle Scholar
  • 43 Mokra D, Tonhajzerova I, Petraskova M, Calkovska A. Effects of dexamethasone on cardiovascular functions in acute phase in meconium-injured rabbits. Pediatr Int 2009; 51 (01) 132-137
    CrossrefPubMedGoogle Scholar
  • 44 Vaage J. Effects of high-dose corticosteroids on the pulmonary circulation. Acta Chir Scand Suppl 1985; 526: 73-82
    PubMedGoogle Scholar
  • 45 Ullian ME. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 1999; 41 (01) 55-64
    CrossrefPubMedGoogle Scholar
  • 46 Perez M, Wedgwood S, Lakshminrusimha S, Farrow KN, Steinhorn RH. Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn. Pulm Circ 2014; 4 (01) 71-81
    CrossrefPubMedGoogle Scholar
  • 47 Perez M, Lakshminrusimha S, Wedgwood S. , et al. Hydrocortisone normalizes oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol 2012; 302 (06) L595-L603
    CrossrefPubMedGoogle Scholar
  • 48 Peeples ES. An evaluation of hydrocortisone dosing for neonatal refractory hypotension. J Perinatol 2017; 37 (08) 943-946
    CrossrefPubMedGoogle Scholar
  • 49 Rudolph AM, Yuan S. Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes. J Clin Invest 1966; 45 (03) 399-411
    CrossrefPubMedGoogle Scholar
  • 50 Pokela ML. Pain relief can reduce hypoxemia in distressed neonates during routine treatment procedures. Pediatrics 1994; 93 (03) 379-383
    PubMedGoogle Scholar
  • 51 Tobias JD. Sedation and analgesia in the pediatric intensive care unit. Pediatr Ann 2005; 34 (08) 636-645
    CrossrefPubMedGoogle Scholar
  • 52 Collins C, Koren G, Crean P, Klein J, Roy WL, MacLeod SM. Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. Anesth Analg 1985; 64 (11) 1078-1080
    PubMedGoogle Scholar
  • 53 Santeiro ML, Christie J, Stromquist C, Torres BA, Markowsky SJ. Pharmacokinetics of continuous infusion fentanyl in newborns. J Perinatol 1997; 17 (02) 135-139
    PubMedGoogle Scholar
  • 54 Saarenmaa E, Neuvonen PJ, Fellman V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J Pediatr 2000; 136 (06) 767-770
    CrossrefPubMedGoogle Scholar
  • 55 Arnold JH, Truog RD, Scavone JM, Fenton T. Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. J Pediatr 1991; 119 (04) 639-643
    CrossrefPubMedGoogle Scholar
  • 56 Orsini AJ, Leef KH, Costarino A, Dettorre MD, Stefano JL. Routine use of fentanyl infusions for pain and stress reduction in infants with respiratory distress syndrome. J Pediatr 1996; 129 (01) 140-145
    CrossrefPubMedGoogle Scholar
  • 57 Fahnenstich H, Steffan J, Kau N, Bartmann P. Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. Crit Care Med 2000; 28 (03) 836-839
    CrossrefPubMedGoogle Scholar
  • 58 Johnson PN, Miller J, Gormley AK. Continuous-infusion neuromuscular blocking agents in critically ill neonates and children. Pharmacotherapy 2011; 31 (06) 609-620
    CrossrefPubMedGoogle Scholar
  • 59 Levene MI, Quinn MW. Use of sedatives and muscle relaxants in newborn babies receiving mechanical ventilation. Arch Dis Child 1992; 67 (7 Spec No): 870-873
    CrossrefPubMedGoogle Scholar
  • 60 Dargaville PA. Respiratory support in meconium aspiration syndrome: a practical guide. Int J Pediatr 2012; 2012: 965159
    PubMedGoogle Scholar
  • 61 Kinsella JP, Truog WE, Walsh WF. , et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131 (1 Pt 1): 55-62
    CrossrefPubMedGoogle Scholar
  • 62 Tworetzky W, Bristow J, Moore P. , et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001; 357 (9250): 118-120
    CrossrefPubMedGoogle Scholar
  • 63 U. S. Food and Drug Administration 2001. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20845_INOmax_Approv.pdf . Accessed May 1, 2018
    PubMed
  • 64 Moon JK, Evey LW, Moon YS, Gest AL, Gomez MR, Wearden ME. Nitric oxide supplied from a 10% source provides inhaled therapy without lowering inspired oxygen fraction. Biomed Instrum Technol 1997; 31 (02) 164-168
    PubMedGoogle Scholar
  • 65 Zapol WM, Rimar S, Gillis N, Marletta M, Bosken CH. Nitric oxide and the lung. Am J Respir Crit Care Med 1994; 149 (05) 1375-1380
    CrossrefPubMedGoogle Scholar
  • 66 Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 1999; 135: 105-149
    PubMedGoogle Scholar
  • 67 Lucas KA, Pitari GM, Kazerounian S. , et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52 (03) 375-414
    PubMedGoogle Scholar
  • 68 Vachiéry JL. Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. Adv Ther 2011; 28 (04) 251-269
    CrossrefPubMedGoogle Scholar
  • 69 Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 1997; 18 (01) 3-7
    CrossrefPubMedGoogle Scholar
  • 70 Kinugasa H, Horigome H, Sugiura M, Saito T, Iijima T, Matsui A. Intravenous prostacyclin combined with inhaled nitric oxide therapy for an infant with alveolar capillary dysplasia. Pediatr Int 2002; 44 (05) 525-527
    CrossrefPubMedGoogle Scholar
  • 71 Kelly LK, Porta NFM, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141 (06) 830-832
    CrossrefPubMedGoogle Scholar
  • 72 Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J Med Assoc Thai 2007; 90 (01) 167-170
    PubMedGoogle Scholar
  • 73 Nakwan N, Wannaro J, Nakwan N. Intravenous iloprost may be an effective first-line treatment for persistent pulmonary hypertension of the newborn in limited-resource situations. Asian Biomed 2013; 7: 873-880
    PubMedGoogle Scholar
  • 74 Janjindamai W, Thatrimontrichai A, Maneenil G, Chanvitan P, Dissaneevate S. Effectiveness and safety of intravenous iloprost for severe persistent pulmonary hypertension of the newborn. Indian Pediatr 2013; 50 (10) 934-938
    CrossrefPubMedGoogle Scholar
  • 75 Nakwan N, Nakwan N, Wannaro J. Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review. Neonatology 2011; 99 (01) 32-37
    CrossrefPubMedGoogle Scholar
  • 76 Ivy DD, Le Cras TD, Horan MP, Abman SH. Increased lung preproET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension. Am J Physiol 1998; 274 (4 Pt 1): L535-L541
    PubMedGoogle Scholar
  • 77 Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012; 32 (08) 608-613
    Google Scholar
  • 78 Steinhorn RH, Fineman J, Kusic-Pajic A. , et al; FUTURE-4 study investigators. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial. J Pediatr 2016; 177: 90-96.e3
    CrossrefPubMedGoogle Scholar
  • 79 McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med 2013; 14 (01) 74-84
    CrossrefPubMedGoogle Scholar
  • 80 Lakshminrusimha S, Keszler M. Persistent pulmonary hypertension of the newborn. Neoreviews 2015; 16 (12) e680-e692
    CrossrefPubMedGoogle Scholar
  • 81 Chandran S, Haqueb ME, Wickramasinghe HT, Wint Z. Use of magnesium sulphate in severe persistent pulmonary hypertension of the newborn. J Trop Pediatr 2004; 50 (04) 219-223
    CrossrefPubMedGoogle Scholar
  • 82 Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A. Magnesium sulphate as an alternative and safe hypertension of the newborn treatment for severe persistent pulmonary hypertension of the newborn. Arch Dis Child Fetal Neonatal Ed 1995; 72 (03) F184-F187
    CrossrefPubMedGoogle Scholar
  • 83 Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007; 3 (03) CD005588
    PubMedGoogle Scholar
  • 84 Kamolvisit W, Jaroensri S, Ratchatapantanakorn B, Nakwan N. Factors and outcomes of persistent pulmonary hypertension of the newborn associated with acute kidney injury in Thai neonates. Am J Perinatol 2018; 35 (03) 298-304
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Sheehy AM, Burson MA, Black SM. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide. Am J Physiol 1998; 274 (5 Pt 1): L833-L841
    PubMedGoogle Scholar